Suppr超能文献

肝细胞癌:解析形态异质性、生长模式和亚型。

Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes.

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

出版信息

Hum Pathol. 2021 Jun;112:86-101. doi: 10.1016/j.humpath.2020.12.009. Epub 2020 Dec 30.

Abstract

Hepatocellular carcinomas are not a homogenous group of tumors but have multiple layers of heterogeneity. This heterogeneity has been studied for many years with the goal to individualize care for patients and has led to the identification of numerous hepatocellular carcinoma subtypes, defined by morphology and or molecular methods. This article reviews both gross and histological levels of heterogeneity within hepatocellular carcinoma, with a focus on histological findings, reviewing how different levels of histological heterogeneity are used as building blocks to construct morphological hepatocellular carcinoma subtypes. The current best practice for defining a morphological subtype is outlined. Then, the definition for thirteen distinct hepatocellular carcinoma subtypes is reviewed. For each of these subtypes, unresolved issues regarding their definitions are highlighted, including recommendations for these problematic areas. Finally, three methods for improving the research on hepatocellular carcinoma subtypes are proposed: (1) Use a systemic, rigorous approach for defining hepatocellular carcinoma subtypes (four-point model); (2) Once definitions for a subtype are established, it should be followed in research studies, as this common denominator enhances the ability to compare results between studies; and (3) Studies of subtypes will be more effective when morphological and molecular results are used in synergistic and iterative study designs where the results of one approach are used to refine and sharpen the results of the other. These and related efforts to better understand heterogeneity within hepatocellular carcinoma are the most promising avenue for improving patient care by individualizing patient care.

摘要

肝细胞癌不是一组同质的肿瘤,而是具有多层次的异质性。多年来,人们一直在研究这种异质性,目的是为患者提供个性化的治疗,并确定了许多肝细胞癌亚型,这些亚型是通过形态和/或分子方法定义的。本文综述了肝细胞癌内在的大体和组织学水平的异质性,重点介绍了组织学发现,探讨了不同层次的组织学异质性如何被用作构建形态学肝细胞癌亚型的构建块。概述了当前定义形态亚型的最佳实践。然后,回顾了十三种不同的肝细胞癌亚型的定义。对于这些亚型中的每一个,都强调了其定义中存在的未解决的问题,包括对这些有问题的领域的建议。最后,提出了三种改进肝细胞癌亚型研究的方法:(1)使用系统的、严格的方法来定义肝细胞癌亚型(四点模型);(2)一旦确定了亚型的定义,就应该在研究中遵循,因为这个共同标准增强了比较研究结果的能力;(3)当形态学和分子学结果在协同和迭代研究设计中协同使用时,研究亚型将更有效,其中一种方法的结果用于细化和锐化另一种方法的结果。这些以及为更好地了解肝细胞癌内部异质性所做的相关努力,是通过为患者提供个性化治疗来改善患者护理的最有前途的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9a/9258523/d92d9ac82710/nihms-1812353-f0001.jpg

相似文献

2
Morphologic Subtypes of Hepatocellular Carcinoma.肝细胞癌的形态学亚型
Gastroenterol Clin North Am. 2017 Jun;46(2):365-391. doi: 10.1016/j.gtc.2017.01.009.
9
Update on hepatocellular carcinoma: Pathologists' review.肝细胞癌最新进展:病理学家述评。
World J Gastroenterol. 2019 Apr 14;25(14):1653-1665. doi: 10.3748/wjg.v25.i14.1653.

引用本文的文献

8
RNA nanotherapeutics for hepatocellular carcinoma treatment.用于治疗肝细胞癌的RNA纳米疗法。
Theranostics. 2025 Jan 1;15(3):965-992. doi: 10.7150/thno.102964. eCollection 2025.

本文引用的文献

5
Pathology of liver disease: advances in the last 50 years.肝脏疾病病理学:过去 50 年的进展。
Hum Pathol. 2020 Jan;95:78-98. doi: 10.1016/j.humpath.2019.08.023. Epub 2019 Sep 4.
6
ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.ESM1 作为巨梁型-块状型肝细胞癌的标志物。
Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验